Exactly! Although I do believe that RP cares about money also. He chose CYDY as he knows that this is major money longer term. Most other Pharma companies only care about trying to make whatever money they can to get to the next product.
Pfizer is in a similar boat as Gilead was the past few years with HIV in that they don’t think this small, financially strapped company can get their better yet to be proven product to market.....and if they later look successful, they can always try to swoop in and get it for a ‘relatively’ small price. Plus they already have a similar product so why spend money on something we already own (too big to fail mentality)? The difference between leronlimab and other drugs in this situation is it has multiple indications whereas most other small companies and their drugs can only treat a small market.
Wait and it’s too late with CYDY IMO. FOMO only works with retail investors, so IMO this will work out great for all of us long retail investors!
News 
Market Data 
Discover 
